IgGenix sprints to clinic with peanut allergy candidate and additional $40M
A small, Eli Lilly-backed biotech has received $40 million on its way to the clinic with a self-administered injection for peanut allergies.
IgGenix unveiled a Series B round on Monday to support what CEO Jessica Grossman calls a “revolutionary” approach to preventing both food and non-food allergies, from dairy to dust to dogs.
When an allergic reaction occurs, the body produces an elevated amount of allergen-specific antibodies called immunoglobulin E, or IgE, triggering an allergic cascade that can cause symptoms from itching to anaphylactic shock. IgGenix is looking to re-engineer IgE antibodies, transforming them into IgG antibodies designed to alleviate the allergic cascade.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.